JNCI Cancer Spectrum最新文献_第3页

Neighborhood homicide rate and odds of colorectal adenoma among adult patients seeking colonoscopy. 邻里凶杀率与寻求结肠镜检查的成年患者患结直肠腺瘤的几率。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-10-29 DOI: 10.1093/jncics/pkae110

Alyshia Hamm, Evgenia Karayeva, Manoela Lima Oliveira, Nabil Kahouadji, Paul Grippo, Patricia G Wolf, Ece Mutlu, Lisa Tussing-Humphreys, Sage J Kim

{"title":"Neighborhood homicide rate and odds of colorectal adenoma among adult patients seeking colonoscopy.","authors":"Alyshia Hamm, Evgenia Karayeva, Manoela Lima Oliveira, Nabil Kahouadji, Paul Grippo, Patricia G Wolf, Ece Mutlu, Lisa Tussing-Humphreys, Sage J Kim","doi":"10.1093/jncics/pkae110","DOIUrl":"10.1093/jncics/pkae110","url":null,"abstract":"Background: Chronic exposure to ambient stressors, including neighborhood crime, may have a detrimental impact on the body's stress response system with implications for colorectal carcinogenesis.Methods: We examined associations between the mean neighborhood homicide rates from 2000 and 2018 and diagnosis of colorectal adenoma among patients at the University of Illinois Health and Hospital System in Chicago, Illinois, between 2015 and 2018.Results: Of the 5,225 patients who underwent colonoscopy and were included in the analytic dataset, 60% had colorectal adenoma. Older age, male sex, and higher body mass index (BMI) were associated with greater odds of colorectal adenoma. The neighborhood homicide rate was associated with identifying as Black and Hispanic and higher BMI. A mediation analysis showed that the neighborhood homicide rate effects on colorectal adenoma were mediated through BMI.Conclusion: The study concluded that older age, male sex, and higher BMI significantly increase the odds of colorectal adenoma, with neighborhood homicide rate indirectly influencing this risk through its association with BMI, particularly among Black and Hispanic individuals.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-reported outcomes (PROs) programs for monitoring symptoms among patients treated with immunotherapy: A scoping review. 用于监测接受免疫疗法患者症状的患者报告结果 (PROs) 计划：范围综述。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-10-28 DOI: 10.1093/jncics/pkae102

Sylvie D Lambert, Sara Soldera, Jordana Kazdan, Francesca Frati, Anita Slominska, Melina Boutin, Vanessa Samouelian, Caroline Letendre, Karine Bilodeau, Doris Howell, Karine Le Breton, Michel-Olivier Gratton

{"title":"Patient-reported outcomes (PROs) programs for monitoring symptoms among patients treated with immunotherapy: A scoping review.","authors":"Sylvie D Lambert, Sara Soldera, Jordana Kazdan, Francesca Frati, Anita Slominska, Melina Boutin, Vanessa Samouelian, Caroline Letendre, Karine Bilodeau, Doris Howell, Karine Le Breton, Michel-Olivier Gratton","doi":"10.1093/jncics/pkae102","DOIUrl":"https://doi.org/10.1093/jncics/pkae102","url":null,"abstract":"Background: Monitoring toxicities among patients receiving immune checkpoint inhibitors (ICIs) using patient-reported outcome (PRO) measures (PROMs) is relatively recent. This scoping review aims to guide decision-making in the development of PROMs ICI programs.Methods: Four electronic databases were searched from inception to January 2024. Data on PROMs ICI programs (eg, PROMs used, frequency) were extracted. Two authors with established inter-rater reliability screened titles, abstracts, and full texts. A narrative synthesis identified patterns in the data.Results: 22 articles described 16 unique multicomponent, electronic PRO programs, mainly developed for remote monitoring of toxicities between appointments. Patients typically completed 18-26 items from the PRO-CTCAE or CTCAE weekly, with high adherence/satisfaction. Commonly monitored symptoms were diarrhea, fatigue, shortness of breath, cough, nausea, decreased appetite, rash, joint pain, pain, and mood. Other features of PROM programs included clinician alerts, with some program only flagging symptoms that had an impact on treatment. Some program also or only sent alerts to patients to contact their clinicians and gave access to symptom management information. In terms of efficacy, the only consistent finding was an increase in QOL.Discussion: The findings of this scoping review provide some indication as to which components of a PROM program are promising. However, as the evidence-based for PROMs among patients receiving ICIs is growing, many questions remain, including which symptoms to monitor, using which PROM, and at what frequency. More trials are needed to answer these questions and to determine how best to implement PROM ICI programs in clinical practice.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Narrative Review of Lifestyle Interventions in Breast Cancer Survivors: Current Evidence and Future Directions. 乳腺癌幸存者生活方式干预的叙述性回顾：当前证据与未来方向。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-10-24 DOI: 10.1093/jncics/pkae108

Kelsey Gabel, Kaitlin Chakos, Manoela Lima Oliveira, Julienne Sanchez Perez, Kate Cares, Natalia Salvatierra Lima, Pamela Ganschow, Betina Yanez, Vijayakrishna Gadi, Lisa Tussing-Humphreys

{"title":"Narrative Review of Lifestyle Interventions in Breast Cancer Survivors: Current Evidence and Future Directions.","authors":"Kelsey Gabel, Kaitlin Chakos, Manoela Lima Oliveira, Julienne Sanchez Perez, Kate Cares, Natalia Salvatierra Lima, Pamela Ganschow, Betina Yanez, Vijayakrishna Gadi, Lisa Tussing-Humphreys","doi":"10.1093/jncics/pkae108","DOIUrl":"https://doi.org/10.1093/jncics/pkae108","url":null,"abstract":"Background: One in eight females will be diagnosed with breast cancer in their lifetime. While medical advances have increased the likelihood of survival, up to 90% of females will gain weight during and after treatment increasing the risk of breast cancer recurrence and obesity related co-morbidities in survivorship. Behavioral lifestyle interventions focused on diet with or without physical activity can provide breast cancer survivors non-pharmacological options to decrease weight gain and cardiometabolic risk.Method: A PubMed search was conducted to identify all behavioral lifestyle interventions focused on diet or diet combined with physical activity longer than 4 weeks of duration in breast cancer survivors that included body weight as an outcome. This review aims to summarize the effects on body weight, body composition and cardiometabolic risk markers are summarized.Results: Based on the review, there is high heterogeneity in type and duration of the intervention to affect weight and cardiometabolic risk in survivorship. Calorie restriction with and without physical activity appears to promote weight loss among breast cancer survivors. However, the effects on cardiometabolic factors are less clear.Conclusion: Future studies should be powered for both body weight and cardiometabolic effects. Researchers should also consider interventions that are: 1) less complex, 2) recruit a more racially and ethnically diverse sample, 3) integrate resistance training, 4) implement the intervention in closer proximity to diagnosis, 5) target weight management in this population before it occurs and 6) analyze body composition in addition to body weight measurements.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic Review of Associations between Anxiety, Depression, and Functional/Biological aging among Cancer Survivors. 癌症幸存者焦虑、抑郁和功能/生物衰老之间关系的系统性回顾。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-10-23 DOI: 10.1093/jncics/pkae100

Brennan Parmelee Streck, Dilorom Sass, Rachelle Brick, Leah Fisk, Alicia A Livinski, Jennifer L Guida

{"title":"Systematic Review of Associations between Anxiety, Depression, and Functional/Biological aging among Cancer Survivors.","authors":"Brennan Parmelee Streck, Dilorom Sass, Rachelle Brick, Leah Fisk, Alicia A Livinski, Jennifer L Guida","doi":"10.1093/jncics/pkae100","DOIUrl":"https://doi.org/10.1093/jncics/pkae100","url":null,"abstract":"Background: Evidence suggests a mind-body component to aging, through which psychological distress from anxiety and depression drives molecular changes that promote early decline (ie, accelerated aging). Cancer survivors experience particularly high rates of anxiety and depression. Some survivors also have accelerated aging, though the relationships between anxiety/depression and aging are not clear. A synthesis of evidence is needed to understand the state of the science and impending priorities.Methods: PubMed, Embase, CINAHL, Web of Science, and PsycNet databases were searched for studies that measured associations between depression, anxiety, and non-chronological aging in cancer survivors (2012 to 2022). Data were methodologically evaluated.Results: Survivorship studies were included if they were peer-reviewed, published in English from 2012-2022, and measured associations between anxiety/depression and aging. 51 studies were included. Just over half were cross-sectional (53%). Foci included functional (n = 35, 69%) and biological (n = 16, 31%). Functional aging measures included frailty, sarcopenia, geriatric assessment, and cognition. Biological aging measures included telomere length, telomerase, age-related inflammatory blood-based biomarkers, renal insufficiency, anemia, and DNA methylation. 223 associations were tested. Associations between anxiety, depression and aging were generally positive, though with varying strengths. Most compelling were associations between functional aging-depression. There were concerns for selection and measurement biases.Conclusions: Findings suggest positive associations between anxiety, depression and aging among cancer survivors. Future work is needed to clarify temporality, develop a consensus on the operationalization of aging, and diversify cohorts.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of undifferentiated carcinomas of the pancreas with and without osteoclast-like giant cells. 有无破骨细胞样巨细胞的胰腺未分化癌的特征。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-10-03 DOI: 10.1093/jncics/pkae097

Jamie N Mills, Valerie Gunchick, Jake Mcgue, Zhaoping Qin, Chandan Kumar-Sinha, Filip Bednar, Noah Brown, Jiaqi Shi, Aaron M Udager, Timothy Frankel, Mark M Zalupski, Vaibhav Sahai

{"title":"Characterization of undifferentiated carcinomas of the pancreas with and without osteoclast-like giant cells.","authors":"Jamie N Mills, Valerie Gunchick, Jake Mcgue, Zhaoping Qin, Chandan Kumar-Sinha, Filip Bednar, Noah Brown, Jiaqi Shi, Aaron M Udager, Timothy Frankel, Mark M Zalupski, Vaibhav Sahai","doi":"10.1093/jncics/pkae097","DOIUrl":"10.1093/jncics/pkae097","url":null,"abstract":"Background: Undifferentiated carcinoma (UC) is a rare subtype of pancreatic cancer differentiated from UC with osteoclast-like giant cells (UC-OGC) in 2019, impacting interpretation of literature that does not distinguish these subtypes. We sought to identify translationally relevant differences between these two variants and as compared to pancreatic ductal adenocarcinoma (PDAC).Methods: We characterized clinical and multiomic differences between UC (n = 32) and UC-OGC (n = 15) using DNA-sequencing (seq), RNA-seq, and multiplex immunofluorescence (mIF) and compared these findings to PDAC.Results: Characteristics at diagnosis were similar between UC and UC-OGC, though UC-OGC was more resectable (p = .009). Across all stages, median overall survival (OS) was shorter for UC than UC-OGC (0.4 vs 10.8 years, respectively; p = .003). This shorter survival was retained after stratification by resection, albeit without statistical significance (1.8 vs 11.9 years, respectively; p = .08). In a subset of patients with available tissue, the genomic landscape was similar between UC (n = 9), UC-OGC (n = 5), and PDAC (n = 159). Bulk RNA-seq was deconvoluted and, along with mIF in UC (n = 13), UC-OGC (n = 5), and PDAC (n = 16), demonstrated statistically significantly increased antigen-presenting cells (APCs), including M2 macrophages and NK cells, and decreased cytotoxic and regulatory T cells (Tregs) in UC and UC-OGC vs PDAC. Findings were similar between UC and UC-OGC except decreased Tregs in UC-OGC (p = .04).Conclusions: In this series, UC is more aggressive than UC-OGC with these variants having more APCs and fewer Tregs than PDAC, suggesting potential for immune-modulating therapies in treatment of these pancreatic cancer subtypes.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations. 糖尿病患者的血糖控制提高了不同人群的肺癌总生存率

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae081

Wayne Y Wu, Brian Luke, Xiao-Cheng Wu, J Jack Lee, Yong Yi, Samuel C Okpechi, Barry Gause, Paras Mehta, Steven I Sherman, Augusto Ochoa, Ethan Dmitrovsky, Xi Liu

{"title":"Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations.","authors":"Wayne Y Wu, Brian Luke, Xiao-Cheng Wu, J Jack Lee, Yong Yi, Samuel C Okpechi, Barry Gause, Paras Mehta, Steven I Sherman, Augusto Ochoa, Ethan Dmitrovsky, Xi Liu","doi":"10.1093/jncics/pkae081","DOIUrl":"10.1093/jncics/pkae081","url":null,"abstract":"Background: The consequence of diabetes on lung cancer overall survival (OS) is debated. This retrospective study used 2 large lung cancer databases to assess comprehensively diabetes effects on lung cancer OS in diverse demographic populations, including health disparity.Methods: The University of Texas MD Anderson Cancer Center database (32 643 lung cancer patients with 11 973 patients with diabetes) was extracted from electronic health records (EHRs) using natural language processing (NLP). Associations were between diabetes and lung cancer prognostic features (age, sex, race, body mass index [BMI], insurance status, smoking, stage, and histopathology). Hemoglobin A1C (HgbA1c) and glucose levels assessed glycemic control. Validation was with a Louisiana cohort (17 768 lung cancer patients with 5402 patients with diabetes) enriched for health disparity cases. Kaplan-Meier analysis, log-rank test, multivariable Cox proportional hazard models, and survival tree analyses were employed.Results: Lung cancer patients with diabetes exhibited marginally elevated OS or no statistically significant difference versus nondiabetic patients. When examining OS for 2 glycemic levels (HgbA1c > 7.0 or glucose > 154 mg/dL vs HgbA1c > 9.0 or glucose > 215 mg/dL), a statistically significant improvement in OS occurred in lung cancer patients with controlled versus uncontrolled glycemia (P < .0001). This improvement spanned sex, age, smoking status, insurance status, stage, race, BMI, histopathology, and therapy. Survival tree analysis revealed that obese and morbidly obese patients with controlled glycemia had higher lung cancer OS than comparison groups.Conclusion: These findings indicate a need for optimal glycemic control to improve lung cancer OS in diverse populations with diabetes.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. CDK4/6 抑制剂的 QTc 延长：随机对照试验的系统回顾和荟萃分析。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae078

Bruno Murad, Pedro C A Reis, Alice Deberaldini Marinho, Ana Carolina Marin Comini, Débora Pinheiro Xavier, Beatriz Mella Soares Pessoa, Farah Raheem, Brenda Ernst, Lida A Mina, Felipe Batalini

{"title":"QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials.","authors":"Bruno Murad, Pedro C A Reis, Alice Deberaldini Marinho, Ana Carolina Marin Comini, Débora Pinheiro Xavier, Beatriz Mella Soares Pessoa, Farah Raheem, Brenda Ernst, Lida A Mina, Felipe Batalini","doi":"10.1093/jncics/pkae078","DOIUrl":"10.1093/jncics/pkae078","url":null,"abstract":"Background: Cyclin-dependent kinases (CDK) 4/6 inhibitors have significantly improved outcomes for patients with ER+/HER2- breast cancer. Nevertheless, they differ from each other in terms of chemical, biological, and pharmacological features, as well as toxicity profiles. We aim to determine whether QTc prolongation is caused by CDK4/6i in general or if it is associated with ribociclib only.Methods: We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing the prevalence of QTc prolongation as an adverse event in HR+ breast cancer patients treated with CDK4/6i vs those without CDK4/6i. We pooled relative risk (RR) and mean difference (MD) with 95% confidence interval (CI) for the binary endpoint of QT prolongation.Results: We included 14 RCTs comprising 16 196 patients, of whom 8576 underwent therapy with CDK4/6i. An increased risk of QTc prolongation was associated with the use of CDK4/6i (RR = 2.35, 95% CI = 1.67 to 3.29, P < .001; I2 = 44%). Subgroup analyses revealed a significant increase in the QTc interval for the ribociclib and palbociclib cohorts. The ribociclib subgroup showed a relative risk of 3.12 (95% CI = 2.09 to 4.65, P < .001; I2 = 12%), whereas the palbociclib subgroup had a relative risk of 1.51 (95% CI = 1.05 to 2.15, P = .025; I2 = 0%).Conclusion: Palbociclib was associated with QTc prolongation; however, the relative risk for any grade QTc was quantitively twice with ribociclib. Furthermore, grade 3 QTc prolongations were observed exclusively with ribociclib. These results are important for guiding clinical decision-making and provide reassurance regarding the overall safety profile of this drug class.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer care and the coconut tree: all in which it lives, and has come before. 癌症护理与椰子树：椰子树生活的一切，以及它的前世今生。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae083

James B Yu

引用次数: 0

Risk of anxiety disorders in men with prostate cancer: a national cohort study. 前列腺癌男性患者罹患焦虑症的风险：一项全国队列研究

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae087

Casey Crump, Pär Stattin, James D Brooks, Jan Sundquist, Kristina Sundquist, Weiva Sieh

{"title":"Risk of anxiety disorders in men with prostate cancer: a national cohort study.","authors":"Casey Crump, Pär Stattin, James D Brooks, Jan Sundquist, Kristina Sundquist, Weiva Sieh","doi":"10.1093/jncics/pkae087","DOIUrl":"10.1093/jncics/pkae087","url":null,"abstract":"Background: Men with prostate cancer (PC) may experience significant psychosocial distress from physical symptoms, treatment side effects, or fear of recurrence. However, little is known about the long-term risk of anxiety disorders in men with PC.Methods: A national cohort study was conducted of 180 189 men diagnosed with PC during 1998-2017 and 1 801 890 age-matched population-based control men in Sweden. Anxiety disorders were ascertained from nationwide outpatient and inpatient records through 2018. Cox regression was used to estimate hazard ratios (HRs) while adjusting for sociodemographic factors and prior psychiatric disorders. Subanalyses explored differences by PC treatment during 2005-2017.Results: In 7.8 million person-years of follow-up, 94 387 (5%) men were diagnosed with anxiety disorders. Men with high-risk PC had a nearly 2-fold higher risk of anxiety disorders than control men without PC (adjusted HR = 1.96, 95% CI = 1.87 to 2.05). This risk was highest in the first 3 months after PC diagnosis (adjusted HR = 2.99, 95% CI = 2.49 to 3.59) but remained significantly elevated 10 or more years later (adjusted HR = 1.53, 95% CI = 1.35 to 1.74). Those treated only with androgen deprivation therapy (ADT) had the highest risk of anxiety disorders (adjusted HR = 2.08, 95% CI = 1.93 to 2.25). Men with low- or intermediate-risk PC had a modestly increased risk (adjusted HR = 1.39, 95% CI = 1.34 to 1.44).Conclusions: In this large national cohort, men with PC had substantially increased risk of anxiety disorders, especially those with high-risk PC and treated only with ADT. Men with PC need close monitoring for timely detection and treatment of anxiety symptoms, particularly shortly after PC diagnosis.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Structural racism and inequity in cancer clinical trial participation: time for solutions. 癌症临床试验参与中的结构性种族主义和不公平现象：是时候找到解决方案了。

IF 3.4

JNCI Cancer Spectrum Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae089

Abhijit Pal, Rayan Saleh Moussa, Ben Smith, Bernadette Brady, Deme Karikios, Frances Boyle, Wei Chua

引用次数: 0